Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GM-CSF in inflammation and autoimmunity.

John A Hamilton1

  • 1Arthritis and Inflammation Research Centre, Department of Medicine, University of Melbourne, The Royal Melbourne Hospital, Victoria 3050, Parkville, Australia. jahami@unimelb.edu.au

Trends in Immunology
|July 23, 2002
PubMed
Summary

Granulocyte macrophage-colony stimulating factor (GM-CSF) is a key regulator of immune cells. Targeting GM-CSF shows promise for treating inflammatory and autoimmune diseases, with greater efficacy than blocking TNF-alpha in arthritis models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CCL17 drives the expression of MMP9 and MMP13 expression via ERK1/2 and NF-κB signaling pathways in rheumatoid arthritis.

Cellular signalling·2026
Same author

Potential Significance of CCL17 in Psoriatic Arthritis.

International journal of rheumatic diseases·2025
Same author

Screening of the FDA-approved drug library identifies CCL17 inhibitors that block arthritic pain.

Scientific reports·2025
Same author

Therapeutic blockade of CCL17 in obesity-exacerbated osteoarthritic pain and disease.

PloS one·2025
Same author

The Anatomic Pathology Hospitalist Model : A Novel Approach to Frozen Section Practice in a Tertiary Care Center.

Archives of pathology & laboratory medicine·2024
Same author

The mode of action of IL-23 in experimental inflammatory arthritic pain and disease.

Arthritis research & therapy·2024

Area of Science:

  • Immunology
  • Molecular Biology
  • Autoimmunity

Background:

  • Granulocyte macrophage-colony stimulating factor (GM-CSF) is a critical regulator of granulocyte and macrophage populations throughout their maturation.
  • Emerging evidence highlights GM-CSF's significant role in the pathogenesis of inflammatory and autoimmune diseases.
  • GM-CSF's involvement in disease progression is supported by observations of disease exacerbation upon administration and therapeutic benefits from its blockade.

Purpose of the Study:

  • To review the regulatory functions of GM-CSF in immune cell development and function.
  • To explore the potential of GM-CSF as a therapeutic target for inflammatory and autoimmune conditions.
  • To discuss the relationship between GM-CSF, interleukin-1, and tumor necrosis factor-alpha in disease contexts.

Main Methods:

Related Experiment Videos

  • Literature review of studies investigating GM-CSF's role in immunity and disease.
  • Analysis of evidence from animal models demonstrating disease modulation by GM-CSF manipulation.
  • Examination of the interplay between GM-CSF and pro-inflammatory cytokines like IL-1 and TNF-alpha.

Main Results:

  • GM-CSF administration can exacerbate inflammatory and autoimmune conditions.
  • Targeting GM-CSF, through gene manipulation or antibody blockade, ameliorates disease in animal models.
  • GM-CSF depletion demonstrates superior disease suppression in arthritis models compared to TNF-alpha inhibition.
  • A significant interdependence exists between GM-CSF production and the release of IL-1 and TNF-alpha.

Conclusions:

  • GM-CSF is a pivotal regulator of myeloid cell function and a significant contributor to inflammatory and autoimmune diseases.
  • Targeting GM-CSF presents a promising therapeutic strategy for managing these conditions.
  • GM-CSF blockade may offer superior therapeutic benefits in certain inflammatory diseases, such as arthritis, compared to targeting TNF-alpha.